65,437 trials
Familial Chylomicronemia Syndrome
Primary: Percent Change From Baseline in Fasting Serum Triglyceride (TG) at Month 10 — -85.7; -89.5; 38.8 Percent change — p=0.0022
Acute Myeloid Leukemia · Blasts 30 Percent or Less of Bone Marrow Nucleated Cells · Chronic Myelomonocytic Leukemia
Primary: Proportion or Participants Experiencing a Dose-limiting Toxicity — 0.0 percentage of participants
Post Cesarean Pain
Primary: Comparing the Morphine Milligram Equivalents (MME) Use in the First 24 Hours. Postoperatively After Cesarean Section — 7.5; 7.5 Morphine milligram equivalents
Low Back Pain
Primary: Oswestry Disability Index (ODI) — 15.1; 15.0; 13.7; 4.6 Scores on a scale
Smoking Cessation
Primary: Biochemically Confirmed Smoking Abstinence Sustained for 6 Months — 26; 45; 78; 61 Participants — p=0.797
Head Trauma · Crushing Skull Injury · Head Injury
Primary: Infrascanner 2500™ Diagnostic Performance — 79; 65; 27; 9 Participants
Cancer of Unknown Primary Site
Primary: Confirmed Objective Response Rate (cORR) by RECISTv1.1 — 40 percentage of participants
Prostatic Neoplasms, Castration-Resistant
Primary: Overall Survival (OS): Adjusted Using Inverse Probability Treatment Weighting (IPTW) — 24.63; 25.77 Months — p==0.0088
Morbid Obesity · Postoperative Pain · Opioid Free Anesthesia
Primary: Postoperative Pain Intensity Measured by the Numerical Rating Scale for Pain (NRS) — 2.5; 0; 3; 1 Score on a scale (0-10)
HIV Prevention
Primary: Changes in HIV Testing — 102; 100; 87; 83 Participants — p=0.484
Presbyopia · Refractive Error · Eye Diseases
Primary: Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision — 48.68; 64.5; 11.49 percentage of participants — p=<0.0001
Transcranial Magnetic Stimulation
Primary: PFC-PPC Effective Connectivity — 0.2177; 0.2248; 0.1911; 0.3157 Hertz — p=0.599
Overweight · Obesity
Primary: Percentage Change in Body Weight — -14.4; -2.5 Percentage change in body weight — p=<0.0001
Skin Diseases
Primary: True Positive — 0 samples
Opioid Use Disorder
Primary: Feasibility - Participant Engagement in the Peer Recovery Support Program — 10 Participants